Press release
KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place in Prague, Czech Republic and virtually, from July 1-3, 2022. The presentations are:\n\n\nIdentification of novel potent oral Factor XIIa inhibitors that block kallikrein kinin system activation in a preclinical model of angioedema: Allen C. Clermont, Director, Preclinical Pharmacology, KalVista Pharmaceuticals, Inc. Results shared as an oral presentation and Q&A on Friday, 1 July 2022 from 16:15 - 17:45 CET in Room E1 and online\n\n\nEfficacy of the Oral Plasma Kallikrein Inhibitor, Sebetralstat, by Attack Location in a Phase 2 Clinical Trial in Patients with Hereditary Angioedema: Emel Aygören-Pürsün, MD, Department for Children and Adolescents, University Hospital Frankfurt, Germany. (Abstract/Poster #XXX). Results shared as a flash talk oral poster presentation on Saturday, 2 July 2022 from 10:30 - 12:00 CET in Room D7 and online\n\n\nEfficacy and Safety of the Oral Plasma Kallikrein Inhibitor, Sebetralstat, in Adolescent and Adult Patients with Hereditary Angioedema: Phase 3 Study Design: Andrea Zanichelli, MD, Department of Internal Medicine, ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco-University of Milan, Italy. e-Poster to be shared online\n\n\nPopulation Pharmacokinetic Analysis of KVD900 in Healthy Adult Volunteers and Patients with Hereditary Angioedema Predicts Similar Exposure in Adolescent Patients: Sinisa Savic, PhD, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK. e-Poster to be shared online\n\n\nAbout KalVista Pharmaceuticals, Inc.\n\nKalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand...